Results 1 to 10 of about 50,591 (247)

Diabetic macular edema [PDF]

Nepalese Journal of Ophthalmology, 2016
Diabetic retinopathy is a frequent manifestation of long standing diabetes mellitus. According to the World Health Organization diabetes affects nine percent of the adult population worldwide (Diabetes Fact Sheet, 2015). Of all of the common diseases of the eye, diabetic retinopathy has a great impact on the working age population and therefore ...
Steven J, Marks, Benjamin P, Hale
  +12 more sources

Diabetic Macular Edema [PDF]

Ophthalmology, 2012
Brasil OFM, 2007, BRIT J OPHTHALMOL, V91, P761, DOI 10.1136-bjo.2006.105783; Gibran SK, 2007, OPHTHALMOLOGY, V114, P890, DOI 10.1016-j.ophtha.2006.11.026; Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016-j.ajo.2006.04.023; Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007-s00417-011-1774-x; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15 ...
Nicola G, Ghazi, Ryan T, Scruggs, Andrew R, Batchelet, Michael W, Compton, Souha S, Allam, James, Patrie, Haytham I, Salti   +6 more
  +10 more sources

Diabetic macular edema

Saudi Journal of Ophthalmology, 2009
A variety of treatment options are available for the treatment of diabetic macular edema. They include laser photocoagulation, anti-VEGF drugs, intravitreal steroids, and vitrectomy with or without release of vitreoretinal traction. A full understanding of the physiological mechanisms of these treatment modalities allows sensible combination of ...
Ritesh Narula, Manisha Agarwal, S.P. Chaudhary, Cyrus Shroff   +3 more
  +9 more sources

Diabetic Macular Edema

Asia-Pacific Journal of Ophthalmology, 2020
Diabetic macular edema (DME) accounts for the majority of decreased vision related to diabetic retinopathy and is a leading cause of vision loss in developed countries. Role of vitrectomy for DME has been proposed for several decades. After introduction of anti-vascular endothelial growth factor (VEGF) treatment, demands for the other treatments, such ...
Ji Eun Lee, Ik Soo Byon, Sung Who Park
openaire   +3 more sources

Laser treatment in diabetic retinopathy [PDF]

, 2007
Diabetic retinopathy is a leading cause of visual impairment and blindness in developed countries due to macular edema and proliferative diabetic retinopathy (PDR). For both complications laser treatment may offer proven therapy: the Diabetic Retinopathy
Akduman L, Aljoscha S. Neubauer, Arend O, Bandello F, Benson WE, Chew EY, Davies N, Ferris, Ferris F, Friberg TR, Gabel VP, Gallemore RP, Giovannini A, Gupta V, Hainsworth DP, Jaffe GJ, Kinyoun J, Klein R, Kroll P, Ladas ID, Laursen ML, Lee CM, Lewis H, Luttrull JK, Maeshima K, Michael W. Ulbig, Neubauer AS, Parolini B, Puliafito CA, Sanchez-Tocino H, Schatz H, Shahidi M, Shimura M, Ulbig MR, Ulbig MW, Ulbig MW, Xu X   +36 more
core   +1 more source

An eighteen-month follow-up study on the effects of intravitreal dexamethasone implant in diabetic macular edema refractory to anti-VEGF therapy [PDF]

, 2016
AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled.
Carnovale, Anna, Mastromatteo, Alessandra, Mollicone, Antonella, Pacella, Elena, Pacella, Fernanda, Romano, Maria Rosaria, Tarquini, Giovanna, Turchetti, Paolo   +7 more
core   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco, BOTTONE, Andrea, Domenica Piraino, Carmen, Mollicone, Antonella, PACELLA, Elena, PACELLA, FERNANDA, Romana Parisiella, Francesca, TURCHETTI, PAOLO   +7 more
core   +1 more source

Central Macular Thickness in Diabetic Macular Edema

Acta Endocrinologica (Bucharest), 2020
Retinal microvascular dysfunction differs in macular edema lesions in the two eyes of the same patient with diabetic retinopathy.To evaluate the relationship between central macular thickness (CMT) and metabolic/systemic factors including anthropometric and laboratory findings, in patients with regressed diabetic retinopathy and a history of pars plana
Güngel, H., Aral, H., Erdenen, F., Gökçe, M., Karaman Erdur, Sevil   +4 more
openaire   +3 more sources

Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]

, 2017
AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA, BASILI, Stefania, LA TORRE, Giuseppe, LENZI, TOMMASO, PACELLA, Elena, PACELLA, FERNANDA, Pascarella, Antonella   +6 more
core   +1 more source